Literature DB >> 25897013

2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer.

W E E Eberhardt1, D De Ruysscher2, W Weder3, C Le Péchoux4, P De Leyn5, H Hoffmann6, V Westeel7, R Stahel8, E Felip9, S Peters10.   

Abstract

To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, first-line/second and further lines of treatment in advanced disease, early-stage disease and locally advanced disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on locally advanced disease.
© The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  ESMO; locally advanced; non-small-cell lung cancer; recommendations; stage III

Mesh:

Substances:

Year:  2015        PMID: 25897013     DOI: 10.1093/annonc/mdv187

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  102 in total

Review 1.  Pembrolizumab (Keytruda).

Authors:  Gerry Kwok; Thomas C C Yau; Joanne W Chiu; Eric Tse; Yok-Lam Kwong
Journal:  Hum Vaccin Immunother       Date:  2016-07-11       Impact factor: 3.452

2.  Multidisciplinary consensus statement on the clinical management of patients with stage III non-small cell lung cancer.

Authors:  M Majem; J Hernández-Hernández; F Hernando-Trancho; N Rodríguez de Dios; A Sotoca; J C Trujillo-Reyes; I Vollmer; R Delgado-Bolton; M Provencio
Journal:  Clin Transl Oncol       Date:  2019-06-06       Impact factor: 3.405

3.  Postoperative Radiotherapy for Resected Stage IIIA-N2 Non-small-cell Lung Cancer: A Population-Based Time-Trend Study.

Authors:  Wan-Qin Zeng; Wen Feng; Li Xie; Chen-Chen Zhang; Wen Yu; Xu-Wei Cai; Xiao-Long Fu
Journal:  Lung       Date:  2019-11-08       Impact factor: 2.584

Review 4.  Salvage surgery after high-dose radiotherapy.

Authors:  Annemie Van Breussegem; Jeroen M Hendriks; Patrick Lauwers; Paul E Van Schil
Journal:  J Thorac Dis       Date:  2017-04       Impact factor: 2.895

5.  Reirradiation of recurrent node-positive non-small cell lung cancer after previous stereotactic radiotherapy for stage I disease : A multi-institutional treatment recommendation.

Authors:  Carsten Nieder; Dirk De Ruysscher; Laurie E Gaspar; Matthias Guckenberger; Minesh P Mehta; Patrick Cheung; Arjun Sahgal
Journal:  Strahlenther Onkol       Date:  2017-04-19       Impact factor: 3.621

6.  Improving survival of patients with locally advanced non-small-cell cancer remains a challenge: comment to PROCLAIM.

Authors:  Robert Pirker
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

7.  Optimized local therapy for locally advanced non-small cell lung cancer.

Authors:  Charlotte Billiet; Dirk De Ruysscher
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

Review 8.  Blood-based biomarkers for precision medicine in lung cancer: precision radiation therapy.

Authors:  Dirk De Ruysscher; Jianyue Jin; Tim Lautenschlaeger; Jin-Xiong She; Zhongxing Liao; Feng-Ming Spring Kong
Journal:  Transl Lung Cancer Res       Date:  2017-12

Review 9.  Targeting stem cells by radiation: From the biological angle to clinical aspects.

Authors:  Alexis Vallard; Sophie Espenel; Jean-Baptiste Guy; Peng Diao; Yaoxiong Xia; Anis El Meddeb Hamrouni; Majed Ben Mrad; Alexander Tuan Falk; Claire Rodriguez-Lafrasse; Chloé Rancoule; Nicolas Magné
Journal:  World J Stem Cells       Date:  2016-08-26       Impact factor: 5.326

Review 10.  Quality of smoking cessation advice in guidelines of tobacco-related diseases: An updated systematic review.

Authors:  Winifred Ekezie; Rachael L Murray; Sanjay Agrawal; Ilze Bogdanovica; John Britton; Jo Leonardi-Bee
Journal:  Clin Med (Lond)       Date:  2020-11       Impact factor: 2.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.